BioRestorative Therapies
BRTX
12 hedge funds and large institutions have $545K invested in BioRestorative Therapies in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
239% more capital inflows, than outflows
Capital inflows: $281K | Capital outflows: $82.9K
1.46% more ownership
Funds ownership: 3.3% → 4.76% (+1.5%)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$164K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$91.3K |
| 3 |
VF
Virtu Financial
New York
|
+$19.1K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$3.62K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$58.3K |
| 2 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$19.2K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
-$5K |
| 4 |
SG
StoneX Group
New York
|
-$433 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5 |
BRTX Hedge Fund Activity: Q3 2025 in Review
12 of the 7,647 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q3 2025, worth a combined $545K — up 32% from $412K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BRTX and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $164K. The largest seller was Morgan Stanley, exiting entirely with an estimated $58.3K sold.
- 12 institutional investors held BioRestorative Therapies (BRTX) as of Q3 2025, down from 13 in Q2 2025.
- Funds reported $545K of BioRestorative Therapies stock for Q3 2025, up 32% quarter-over-quarter.
- 2 funds opened new BioRestorative Therapies positions in Q3 2025 and 3 closed out, a net change of -1 holder.
- The largest BioRestorative Therapies buyer in Q3 2025 was Citadel Advisors, an estimated $164K added.
- The largest BioRestorative Therapies seller in Q3 2025 was Morgan Stanley, an estimated $58.3K sold.
Based on aggregated 13F filings for Q3 2025.